{
 "companyname": "HEMISPHERX BIOPHARMA INC",
 "symbol": "HEB",
 "description": "Biological Products, Except Diagnostic Substances",
 "quarters": [
  {
   "cik": "0000946644",
   "companyname": "HEMISPHERX BIOPHARMA INC",
   "entityid": 9245,
   "primaryexchange": "NYSE MKT",
   "primarysymbol": "HEB",
   "siccode": "2836",
   "sicdescription": "Biological Products, Except Diagnostic Substances",
   "usdconversionrate": 1,
   "restated": false,
   "receiveddate": "11/16/2015",
   "preliminary": false,
   "periodlengthcode": "m",
   "periodlength": 3,
   "periodenddate": "9/30/2015",
   "original": true,
   "formtype": "10-Q",
   "fiscalyear": 2015,
   "fiscalquarter": 3,
   "dcn": "0000946644-15-000067",
   "currencycode": "USD",
   "crosscalculated": true,
   "audited": "false",
   "amended": false,
   "changeincurrentassets": -257000,
   "changeincurrentliabilities": 229000,
   "changeininventories": -317000,
   "dividendspaid": null,
   "effectofexchangerateoncash": null,
   "capitalexpenditures": 14000,
   "cashfromfinancingactivities": 383000,
   "cashfrominvestingactivities": 2438000,
   "cashfromoperatingactivities": -3502000,
   "cfdepreciationamortization": 292000,
   "changeinaccountsreceivable": null,
   "investmentchangesnet": 2443000,
   "netchangeincash": -681000,
   "totaladjustments": 301000,
   "ebit": -3983000,
   "costofrevenue": 353000,
   "discontinuedoperations": null,
   "equityearnings": null,
   "accountingchange": null,
   "extraordinaryitems": null,
   "grossprofit": -330000,
   "incomebeforetaxes": -3803000,
   "interestexpense": -1000,
   "netincome": -3803000,
   "netincomeapplicabletocommon": -3803000,
   "researchdevelopmentexpense": 1968000,
   "totalrevenue": 23000,
   "sellinggeneraladministrativeexpenses": 1685000,
   "commonstock": 248000,
   "deferredcharges": null,
   "cashandcashequivalents": 1161000,
   "cashcashequivalentsandshortterminvestments": 12375000,
   "goodwill": null,
   "intangibleassets": 883000,
   "inventoriesnet": 1326000,
   "minorityinterest": null,
   "otherassets": 134000,
   "othercurrentassets": null,
   "othercurrentliabilities": null,
   "otherequity": null,
   "otherliabilities": null,
   "preferredstock": 0,
   "propertyplantequipmentnet": 11501000,
   "retainedearnings": -289862000,
   "totalassets": 26497000,
   "totalcurrentassets": 13979000,
   "totalcurrentliabilities": 3327000,
   "totalliabilities": 3327000,
   "totallongtermdebt": null,
   "totalreceivablesnet": null,
   "totalshorttermdebt": 3000,
   "totalstockholdersequity": 23170000,
   "treasurystock": null
  },
  {
   "cik": "0000946644",
   "companyname": "HEMISPHERX BIOPHARMA INC",
   "entityid": 9245,
   "primaryexchange": "NYSE MKT",
   "primarysymbol": "HEB",
   "siccode": "2836",
   "sicdescription": "Biological Products, Except Diagnostic Substances",
   "usdconversionrate": 1,
   "restated": false,
   "receiveddate": "8/12/2015",
   "preliminary": false,
   "periodlengthcode": "m",
   "periodlength": 3,
   "periodenddate": "6/30/2015",
   "original": true,
   "formtype": "10-Q",
   "fiscalyear": 2015,
   "fiscalquarter": 2,
   "dcn": "0000946644-15-000048",
   "currencycode": "USD",
   "crosscalculated": true,
   "audited": "false",
   "amended": false,
   "changeincurrentassets": -435000,
   "changeincurrentliabilities": -39000,
   "changeininventories": -529000,
   "dividendspaid": null,
   "effectofexchangerateoncash": null,
   "capitalexpenditures": -193000,
   "cashfromfinancingactivities": 4043000,
   "cashfrominvestingactivities": -163000,
   "cashfromoperatingactivities": -4980000,
   "cfdepreciationamortization": 286000,
   "changeinaccountsreceivable": null,
   "investmentchangesnet": 54000,
   "netchangeincash": -1100000,
   "totaladjustments": -135000,
   "ebit": -4901000,
   "costofrevenue": 507000,
   "discontinuedoperations": null,
   "equityearnings": null,
   "accountingchange": null,
   "extraordinaryitems": null,
   "grossprofit": -460000,
   "incomebeforetaxes": -4845000,
   "interestexpense": 0,
   "netincome": -4845000,
   "netincomeapplicabletocommon": -4845000,
   "researchdevelopmentexpense": 2439000,
   "totalrevenue": 47000,
   "sellinggeneraladministrativeexpenses": 2002000,
   "commonstock": 245000,
   "deferredcharges": null,
   "cashandcashequivalents": 1842000,
   "cashcashequivalentsandshortterminvestments": 15714000,
   "goodwill": null,
   "intangibleassets": 951000,
   "inventoriesnet": 1009000,
   "minorityinterest": null,
   "otherassets": 134000,
   "othercurrentassets": null,
   "othercurrentliabilities": null,
   "otherequity": null,
   "otherliabilities": null,
   "preferredstock": 0,
   "propertyplantequipmentnet": 11720000,
   "retainedearnings": -286059000,
   "totalassets": 29866000,
   "totalcurrentassets": 17061000,
   "totalcurrentliabilities": 3102000,
   "totalliabilities": 3102000,
   "totallongtermdebt": null,
   "totalreceivablesnet": null,
   "totalshorttermdebt": 7000,
   "totalstockholdersequity": 26764000,
   "treasurystock": null
  },
  {
   "cik": "0000946644",
   "companyname": "HEMISPHERX BIOPHARMA INC",
   "entityid": 9245,
   "primaryexchange": "NYSE MKT",
   "primarysymbol": "HEB",
   "siccode": "2836",
   "sicdescription": "Biological Products, Except Diagnostic Substances",
   "usdconversionrate": 1,
   "restated": false,
   "receiveddate": "5/12/2015",
   "preliminary": false,
   "periodlengthcode": "m",
   "periodlength": 3,
   "periodenddate": "3/31/2015",
   "original": true,
   "formtype": "10-Q",
   "fiscalyear": 2015,
   "fiscalquarter": 1,
   "dcn": "0000946644-15-000013",
   "currencycode": "USD",
   "crosscalculated": false,
   "audited": "false",
   "amended": false,
   "changeincurrentassets": -513000,
   "changeincurrentliabilities": -608000,
   "changeininventories": -480000,
   "dividendspaid": null,
   "effectofexchangerateoncash": null,
   "capitalexpenditures": -47000,
   "cashfromfinancingactivities": 5235000,
   "cashfrominvestingactivities": -192000,
   "cashfromoperatingactivities": -4257000,
   "cfdepreciationamortization": 251000,
   "changeinaccountsreceivable": null,
   "investmentchangesnet": 0,
   "netchangeincash": 786000,
   "totaladjustments": -812000,
   "ebit": -4923000,
   "costofrevenue": 372000,
   "discontinuedoperations": null,
   "equityearnings": null,
   "accountingchange": null,
   "extraordinaryitems": null,
   "grossprofit": -336000,
   "incomebeforetaxes": -3445000,
   "interestexpense": -2000,
   "netincome": -3445000,
   "netincomeapplicabletocommon": -3445000,
   "researchdevelopmentexpense": 2674000,
   "totalrevenue": 36000,
   "sellinggeneraladministrativeexpenses": 1913000,
   "commonstock": 226000,
   "deferredcharges": null,
   "cashandcashequivalents": 2942000,
   "cashcashequivalentsandshortterminvestments": 17005000,
   "goodwill": null,
   "intangibleassets": 935000,
   "inventoriesnet": 480000,
   "minorityinterest": null,
   "otherassets": 134000,
   "othercurrentassets": null,
   "othercurrentliabilities": null,
   "otherequity": null,
   "otherliabilities": null,
   "preferredstock": 0,
   "propertyplantequipmentnet": 11805000,
   "retainedearnings": -281214000,
   "totalassets": 30791000,
   "totalcurrentassets": 17917000,
   "totalcurrentliabilities": 3821000,
   "totalliabilities": 3821000,
   "totallongtermdebt": null,
   "totalreceivablesnet": null,
   "totalshorttermdebt": 15000,
   "totalstockholdersequity": 26970000,
   "treasurystock": null
  }
 ]
}